Maria-del-Carmen Cardenas-Aguayo

Dr. Maria-del-Carmen Cardenas-Aguayo

Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
Maria-del-Carmen Silva-LuceroMaria-del-Carmen Silva-Lucero
Maria-del-Carmen Silva-Lucero
DFDiego-Salvador Flores-Morelos
Diego-Salvador Flores-Morelos
JGJazmin Gallardo-Nieto
Jazmin Gallardo-Nieto
Gustavo Lopez-ToledoGustavo Lopez-Toledo
Gustavo Lopez-Toledo
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
Autophagy is a highly conserved lysosomal degradation pathway active at basal levels in all cells. However, under stress conditions, such as a lack of nutrients or trophic factors, it works as a survival mechanism that allows the generation of metabolic precursors for the proper functioning of the cells until the nutrients are available. Neurons, as post-mitotic cells, depend largely on autophagy to maintain cell homeostasis to get rid of damaged and/or old organelles and misfolded or aggregated proteins. Therefore, the dysfunction of this process contributes to the pathologies of many human diseases. Furthermore, autophagy is highly active during differentiation and development. In this review, we describe the current knowledge of the different pathways, molecular mechanisms, factors that induce it, and the regulation of mammalian autophagy. We also discuss its relevant role in development and disease. Finally, here we summarize several investigations demonstrating that autophagic abnormalities have been considered the underlying reasons for many human diseases, including liver disease, cardiovascular, cerebrovascular diseases, neurodegenerative diseases, neoplastic diseases, cancers, and, more recently, infectious diseases, such as SARS-CoV-2 caused COVID-19 disease.

Verified
Journal Article
Open access
PDF file
AGANDRADE JESUS GUERRERO
ANDRADE JESUS GUERRERO
ABAlberto Santiago Balmaseda
Alberto Santiago Balmaseda
Paola Jeronimo AguilarPaola Jeronimo Aguilar
Paola Jeronimo Aguilar
IRIsaac Vargas Rodríguez
Isaac Vargas Rodríguez
ASAna Ruth Cadena Suárez
Ana Ruth Cadena Suárez
Luis O. Soto-RojasLuis O. Soto-Rojas
Luis O. Soto-Rojas
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the world. It is classified as familial and sporadic. The dominant familial or autosomal presentation represents 1–5% of the total number of cases. It is categorized as early onset (EOAD; <65 years of age) and presents genetic mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or the Amyloid precursor protein (APP). Sporadic AD represents 95% of the cases and is categorized as late-onset (LOAD), occurring in patients older than 65 years of age. Several risk factors have been identified in sporadic AD; aging is the main one. Nonetheless, multiple genes have been associated with the different neuropathological events involved in LOAD, such as the pathological processing of Amyloid beta (Aβ) peptide and Tau protein, as well as synaptic and mitochondrial dysfunctions, neurovascular alterations, oxidative stress, and neuroinflammation, among others. Interestingly, using genome-wide association study (GWAS) technology, many polymorphisms associated with LOAD have been identified. This review aims to analyze the new genetic findings that are closely related to the pathophysiology of AD. Likewise, it analyzes the multiple mutations identified to date through GWAS that are associated with a high or low risk of developing this neurodegeneration. Understanding genetic variability will allow for the identification of early biomarkers and opportune therapeutic targets for AD.

30 September 2014 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
SDSteven DeRosa
Steven DeRosa
MMMarco Antonio Meraz-Ríos
Marco Antonio Meraz-Ríos

10 August 2010 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
JBJulie Blanchard
Julie Blanchard
LWLukas Wanka
Lukas Wanka
YTYunn-Chyn Tung
Yunn-Chyn Tung
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
FLFrank M. LaFerla
Frank M. LaFerla
IGInge Grundke-Iqbal
Inge Grundke-Iqbal

8 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
SKSyed Faraz Kazim
Syed Faraz Kazim
IGInge Grundke-Iqbal
Inge Grundke-Iqbal
Khalid IqbalKhalid Iqbal
Khalid Iqbal
The level of brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, is down regulated in Alzheimer’s disease (AD), Parkinson’s disease (PD), depression, stress, and anxiety; conversely the level of this neurotrophin is increased in autism spectrum disorders. Thus, modulating the level of BDNF can be a potential therapeutic approach for nervous system pathologies. In the present study, we designed five different tetra peptides (peptides B-1 to B-5) corresponding to different active regions of BDNF. These tetra peptides were found to be non-toxic, and they induced the expression of neuronal markers in mouse embryonic day 18 (E18) primary hippocampal neuronal cultures. Additionally, peptide B-5 induced the expression of BDNF and its receptor, TrkB, suggesting a positive feedback mechanism. The BDNF peptides induced only a moderate activation (phosphorylation at Tyr 706) of the TrkB receptor, which could be blocked by the Trk’s inhibitor, K252a. Peptide B-3, when combined with BDNF, potentiated the survival effect of this neurotrophin on H2O2-treated E18 hippocampal cells. Peptides B-3 and B-5 were found to work as partial agonists and as partial antagonists competing with BDNF to activate the TrkB receptor in a dose-dependent manner. Taken together, these results suggest that the described BDNF tetra peptides are neurotrophic, can modulate BDNF signaling in a partial agonist/antagonist way, and offer a novel therapeutic approach to neural pathologies where BDNF levels are dysregulated.

2 September 2003 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
JSJesús Santa-Olalla
Jesús Santa-Olalla
JBJosé-Manuel Baizabal
José-Manuel Baizabal
MFMariana Fregoso
Mariana Fregoso
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
LCLuis Covarrubias
Luis Covarrubias